TALLAHASSEE, FL, July 7, 2020 /PRNewswire/ – Trulieve Cannabis Corp (CSE: TRUL) (OTC: TCNNF) (“Trulieve” or the “Company”), a leading and top-performing cannabis company in the United States, today announces the launch of a new product to further extend its variety of quality cannabis offerings for Florida patients. TruKief will provide patients with an attractive addition to TruFlower in rotating strains of Sativa, Indica, and Hybrid.
TruKief is a raw cannabinoid medicine derived from flower. It is a cost-effective solution that is administered through inhalation and delivers a higher percentage of cannabinoids than flower. TruKief is isolated mechanically, with controlled temperature, from our flower processing lines. This high potency flower product has less plant material, reducing risk of potential irritation.
“Trulieve is thrilled to offer TruKief to our community and meet the growing demand for a high THC product,” said Valda Coryat, chief marketing officer at Trulieve. “For patients focused on minimizing the cost of their relief, looking for experimental flexibility, or those that desire solvent-less concentrates, Trulieve continues to be the leading source for both quality and accessibility with our new TruKeif option.”
TruKief will be available starting July 7th in Trulieve’s dispensaries, and via online ordering for delivery or pick up in-store or curbside.
Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California, Massachusetts and Connecticut. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF.
This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
To learn more about Trulieve, visit www.Trulieve.com.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company and statements with regard to the Report and the Company’s response thereto. Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.
SOURCE Trulieve Cannabis Corp.